Allecra Therapeutics and Shanghai Haini Pharmaceutical Announce Exclusive Licensing Agreement for Cefepime/enmetazobactam for Greater China
• Allecra, subject to the satisfaction of terms and conditions as set forth in the Exclusive Licensing Agreement, is to receive an upfront cash payment and is eligible to receive additional development and commercial milestone payments with an overall deal value of $78 million, in addition to royalties
• Shanghai Haini gains exclusive manufacturing, development and commercial rights for the licensed territory

To read the press release, please click here


Peijia Medical Ltd and HighLife SAS, a Paris-based medical device company, focused on the development of a unique transeptal mitral valve replacement (“TMVR”) system to treat patients suffering from mitral regurgitation, announced that they have entered into a license agreement pursuant to which HighLife has granted to Peijia an exclusive license regarding certain proprietary TMVR products currently in development by HighLife. Under the Agreement, Peijia is entitled to, among other things, manufacture, develop, and commercialize the products in the greater China region, and HighLife is in return entitled to receive an upfront fee and subsequent milestone payments.

Interventional treatment for mitral regurgitation (“MR”) is considered to be one of the most challenging areas in the field of structural heart disease, yet also represents huge market potential. The TMVR technology developed by HighLife uses a transeptal approach to treat patients with MR, and is currently evaluated in international clinical studies in more than 20 sites on three continents.

To read the press release, please click here

Partager sur :

d'autres actualités Non classifié(e)